Resistance to RAF inhibitors in melanoma
Resistance to RAF inhibitor (i) blockade of signaling through the MEK-ERK1/2 pathway can occur via acquired mutation in N-RAS (Q61K or Q61R) or up-regulation of receptor tyrosine kinases (RTK). These mechanisms enhance RAS activity, which promotes C-RAF dimerization and activation. MEK-ERK1/2 pathway activation can also occur through mutations in the B-RAF target, MEK1 (P124L), and via up-regulation of the MAP3K, Cot1. Activation of the parallel PI-3 kinase-Akt pathway is promoted by loss of PTEN expression/activity often through mutation and up-regulation of RTKs including IGF-1R and possibly PDGFRβ. Re-activation of the ERK1/2 pathway and PI-3K-Akt signaling promote G1/S cell cycle events including cyclin D1 up-regulation and down-regulation of the cyclin-dependent inhibitor, p27Kip1. Additionally, these pathways promote survival events by promoting expression of the anti-apoptotic protein, Mcl-1, as well as down-modulating levels of the pro-apoptotic BH3-only proteins, Bim-EL and Bmf. Alterations in the expression of these cell cycle and survival proteins may also promote resistance to RAF inhibitors.
Publication
Mechanisms of resistance to RAF inhibitors in melanoma. (2011) Andrew E. Aplin, et al. J Invest Dermatol. 2011 Sep;131(9):1817-1820. Figure: F1.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | PDGFRB | PDGFRB | ncbigene_symbol | PDGFRB | 5159 |
| Homo sapiens | Primates | IGF-1R | IGF1R | ncbigene_symbol | IGF1R | 3480 |
| Homo sapiens | Primates | RAS | RAS | famplex_relations | KRAS | 3845 |
| Homo sapiens | Primates | RAS | RAS | famplex_relations | HRAS | 3265 |
| Homo sapiens | Primates | RAS | RAS | famplex_relations | NRAS | 4893 |
| Homo sapiens | Primates | BRAF | BRAF | ncbigene_symbol | BRAF | 673 |
| Homo sapiens | Primates | PI3K | PI3K | ncbigene_synonym | PIK3CA | 5290 |
| Homo sapiens | Primates | PI3K | PI3K | ncbigene_synonym | PIK3CB | 5291 |
| Homo sapiens | Primates | PI3K | PI3K | ncbigene_synonym | PIK3CD | 5293 |
| Homo sapiens | Primates | PI3K | PI3K | ncbigene_synonym | PIK3CG | 5294 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R3 | 8503 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R4 | 30849 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R5 | 23533 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R6 | 146850 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R1 | 5295 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R2 | 5296 |
| Homo sapiens | Primates | CRAF | CRAF | ncbigene_synonym | RAF1 | 5894 |
| Homo sapiens | Primates | PTEN | PTEN | ncbigene_symbol | PTEN | 5728 |
| Homo sapiens | Primates | MEK | MEK | ncbigene_synonym | MAP2K7 | 5609 |
| Homo sapiens | Primates | MEK | MEK | famplex_relations | MAP2K1 | 5604 |
| Homo sapiens | Primates | MEK | MEK | famplex_relations | MAP2K2 | 5605 |
| Homo sapiens | Primates | AKT3 | AKT3 | ncbigene_symbol | AKT3 | 10000 |
| Homo sapiens | Primates | ERK | ERK | ncbigene_synonym | EPHB2 | 2048 |
| Homo sapiens | Primates | ERK | ERK | ncbigene_synonym | MAPK1 | 5594 |
| Homo sapiens | Primates | ERK | ERK | famplex_relations | MAPK3 | 5595 |
| Homo sapiens | Primates | CyclinD1 | CCND1 | ncbigene_symbol | CCND1 | 595 |
| Homo sapiens | Primates | Bmf | BMF | ncbigene_symbol | BMF | 90427 |
| Homo sapiens | Primates | Mcl-1 | MCL-1 | ncbigene_synonym | MCL1 | 4170 |
| Homo sapiens | Primates | p27Kip1 | P27KIP1 | ncbigene_synonym | CDKN1B | 1027 |
| Word | Match | MeSH | Name | ChEBI |
|---|
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|---|---|---|---|
| Cancer | NA | |||
| Cardiomyopathy | NA | |||
| Lung cancer | NA | |||
| Noonan syndrome | NA |